[
  {
    "clause_index": 4,
    "start_char": 2693,
    "end_char": 3206,
    "original": "(a) This Agreement shall have an Initial Term of three (3) years. The Term shall commence on July 23, 2013 and shall expire on July 22, 2016, unless otherwise terminated earlier pursuant to Section 9 of this Agreement. The period from July 23, 2013 to July 22, 2014 shall be referred to as the \u201cFirst Contract Year\u201d. The period from July 23, 2014 to July 22, 2015 shall be referred to as the \u201cSecond Contract Year\u201d. The period from July 23, 2015 to July 22, 2016 shall be referred to as the \u201cThird Contract Year\u201d.",
    "ollama_generated": "(a) This Agreement will have an Initial Term of three (3) years, commencing on July 23, 2013 and concluding on July 22, 2016. However, either Party may terminate this Agreement at any time prior to its expiration, as provided in Section 9 of this Agreement. For the sake of clarity, the period from July 23, 2013 to July 22, 2014 will hereafter be referred to as the \"Initial Contract Period\", with subsequent annual periods being labeled as \"Subsequent Contract Years\". The duration of each Subsequent Contract Year shall be one (1) year from the expiration of the preceding year, unless terminated earlier.",
    "contradiction_score": 0.08259062469005585,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 6162,
    "end_char": 6772,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Products. As used in this Agreement, \u201cProducts\u201d shall mean dietary supplements manufactured within the fifty states of the United States of America\u037e provided, however, MusclePharm shall not produce during the Term (and any renewal Term, if any) any diet pills and/or sexual enhancement products\u037e provided, further, that fat burning products, Shred Matrix and Live Shredded products and products that increase testosterone levels currently produced by MusclePharm as of the date hereof shall be part of the definition of Products for the purpose of this Agreement.",
    "ollama_generated": "Clause:\nAs defined in this Agreement, \"Products\" encompasses dietary supplements exclusively manufactured within the fifty states of the United States of America, subject to the following exceptions: MusclePharm is prohibited from manufacturing diet pills and/or sexual enhancement products during the initial term and any subsequent renewals. However, certain existing product lines, including but not limited to fat burning products such as Shred Matrix and Live Shredded, and testosterone-boosting products as of the effective date, shall remain within the scope of \"Products\" for the purposes of this Agreement.",
    "contradiction_score": 0.0245626512914896,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 21,
    "start_char": 12748,
    "end_char": 13819,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Advertisements, Print Media, and Promotional Items . Endorser agrees that during the Term MusclePharm shall have the right to use, worldwide, Endorser\u2019s Name and Appearance Rights (as specified in Section 6) to advertise MusclePharm and its Products and Licensed Products in print media, and in all other forms of media (other than telephone marketing or texting campaigns) including, but not limited to, point of sale material, premiums and novelties, direct marketing material, and radio, television, electronic, and computer media (including but not limited to MusclePharm\u2019s Internet and social media websites) . Print media will also include promotional items on which Endorser\u2019s approved picture\u037e approved likeness, or facsimile signature may appear. Endorser will have the right to approve, in writing via his representative\u2019s office, all advertising materials which utilize Endorser\u2019s Name and Appearance Rights, but Endorser will not unreasonably withhold approval and will promptly respond to all approval requests.",
    "ollama_generated": "Clause:\nSource: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Advertisements, Print Media, and Promotional Items . Endorser grants MusclePharm a non-exclusive, worldwide license during the Term to utilize, Endorser\u2019s Name, Likeness, and Signature Rights (as defined in Section 6), for the purpose of advertising MusclePharm, its Products, and Licensed Products across various mediums (other than telemarketing or texting campaigns) including but not limited to point of sale materials, premiums and novelties, direct marketing material, radio, television, electronic, and computer media (including MusclePharm's Internet and social media websites). The license extends to promotional items bearing Endorser\u2019s approved image.\n\nMusclePharm shall provide written notice of all advertising materials that use Endorser\u2019s Rights. While Endorser retains the right to reject any material, such rejections will not be unreasonable and prompt responses are expected from Endorser or their authorized representative.",
    "contradiction_score": 0.10772199928760529,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 23,
    "start_char": 14242,
    "end_char": 14760,
    "original": "(d) Use-Up Period . During the Term, the right to use Endorser's Name and Appearance Rights granted to MusclePharm in this Section shall extend for six (6) months beyond the expiration of this Agreement (the \"Use-up Period\"). MusclePharm shall create no new advertising during the Use-up Period using Endorser's Name and Appearance, but shall have the right to use during the Use-up Period Endorser's Name and Appearance in advertisements and promotional materials created before the expiration date of this Agreement.",
    "ollama_generated": "(d) Transitional Period. During the term of this agreement, MusclePharm shall be permitted to utilize Endorser's Name and Appearance Rights, as granted under this section, for a period of six (6) months following the termination or expiration of this agreement (hereinafter referred to as the \"Transitional Period\"). During this period, MusclePharm may choose not to create new advertisements featuring Endorser's Name and Appearance, but any pre-existing advertisements or promotional materials incorporating Endorser's likeness may still be used. This right applies only to materials created prior to the termination or expiration date of this agreement.\n\nThis revised clause aims to provide a more balanced perspective by allowing MusclePharm to continue using pre-existing materials, but it also clarifies that they are not obligated to create new advertisements during the transitional period. Furthermore, the use of \"may choose\" and \"applies only\" provides a clearer understanding of MusclePharm's options and the scope of the rights granted during this period.",
    "contradiction_score": 0.0044596088118851185,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 29,
    "start_char": 16851,
    "end_char": 16866,
    "original": "5. Scheduling :",
    "ollama_generated": "5. Timeframe Flexibility:\n\nThe Parties acknowledge that unexpected events may necessitate adjustments to the project timeline. As such, each Party shall strive to adhere to the established schedule but may request a reasonable extension if unforeseen circumstances arise, subject to the other Party's consent. Any granted extension shall not be deemed a waiver of any rights or obligations under this Agreement.",
    "contradiction_score": 0.1157064288854599,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 30,
    "start_char": 16866,
    "end_char": 17713,
    "original": "(a) The Appearances, the Production Day, the Licensed Product launch and related media campaign, the interview of Endorser by MusclePharm, and all advertising and promotional activities requested by MusclePharm and approved by Endorser shall be scheduled by mutual agreement and subject to Endorser\u2019s other business activities and commitments occurring during the Term of this Agreement. Endorser\u2019s commitments pursuant to this Agreement shall be scheduled so as not to conflict with Endorser\u2019s other commitments. Endorser agrees that he will in good faith make every reasonable effort, given his other commitments, to give priority to the fulfillment of his obligations pursuant to this Agreement. The parties shall confer periodically for the purpose of coordinating and scheduling Endorser\u2019s advertising and promotional activities and services.",
    "ollama_generated": "(a) The Appearances, the Production Day, the Launch of the Licensed Product, associated media campaigns, interviews conducted by MusclePharm featuring the Endorser, and any requested advertising or promotional activities will be scheduled collaboratively, taking into account the Endorser's existing business obligations and commitments during the Term of this Agreement. The scheduling of Endorser's duties under this Agreement shall prioritize accommodating these other commitments, to the extent feasible, without compromising the timely fulfillment of said obligations. MusclePharm acknowledges that the Endorser may need to reschedule or modify certain activities due to his other commitments and expects the Endorser to do so in a prompt and professional manner. The parties will hold regular discussions to coordinate and adapt the scheduling of the Endorser's advertising and promotional activities and services accordingly.",
    "contradiction_score": 0.000762331357691437,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 39,
    "start_char": 22748,
    "end_char": 22787,
    "original": "6B. Sample Products for Endorser\u2019s Use:",
    "ollama_generated": "6B. Utilization of Sample Products by the Endorser:\n\nIn this Agreement, the Company shall provide the Endorser with certain Sample Products for evaluation and promotional purposes. The Endorser acknowledges that they shall use these Sample Products responsibly and in accordance with their intended purpose. Notably, the Endorser's obligation to promote or endorse the Sample Products is not dependent on the quality of the products received but rather on their personal preference and overall perception of the product. In the event that the Endorser has a negative opinion of the Sample Product, they are expected to express this feedback constructively and professionally while being mindful of the potential impact on the Company's reputation. The Company will not be held responsible for any inconvenience or damages incurred by the Endorser as a result of using the Sample Products unless such inconvenience or damage arises from the Company's gross negligence or intentional misconduct.",
    "contradiction_score": 0.010756672360002995,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 47,
    "start_char": 25152,
    "end_char": 26100,
    "original": "(v)During the Term and during the sell-off period, MusclePharm shall make royalty payments in U.S. dollars for the respective quarters ending on the last day of September, December, March and June (each, a \u201cRoyalty Period\u201d) within thirty (30) days from the end of each quarterly period. Each such royalty payment shall include an itemized statement showing the nature and source of such royalties, including (i) the number of units of Licensed Products sold (by country and customer)\u037e (ii) the total number of units returned for which credit was given and the total dollar amount of such credits, and (iii) the total gross sales and the total royalties due with respect to such gross sales, and each itemized statement shall be certified by a duly authorized officer of MusclePharm. Such statements shall be in the form attached hereto as Exhibit \u201cB\u201d and furnished to Lender whether or not any Licensed Products were sold during the Royalty Period.",
    "ollama_generated": "(v) During the Term and the subsequent royalty payment period, Lender will receive royalty payments in U.S. dollars for the respective quarters ending on the last day of September, December, March, and June (each, a \"Royalty Period\"). MusclePharm shall make these payments within sixty (60) days from the start of each subsequent quarterly period, instead of thirty (30) days from the end. Each such royalty payment will include an itemized statement detailing the nature and source of royalties as follows:\n\n  (i) The number of units of Licensed Products sold (by country and customer)\u037e\n  (ii) The total number of units returned for which credit was given, but without specifying the total dollar amount of such credits;\n  (iii) The total gross sales and the total royalties due with respect to such gross sales, but without providing a breakdown of these figures.\n\nEach itemized statement will be certified by a duly authorized officer of MusclePharm, as before, and in the same form attached hereto as Exhibit \"B\". However, these statements will only be furnished to Lender if royalties are actually due, i.e., if products were sold during the Royalty Period.",
    "contradiction_score": 0.481068879365921,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 49,
    "start_char": 26340,
    "end_char": 26664,
    "original": "(vii)Receipt or acceptance by Lender (or its authorized representative) of a royalty statement or receipt or acceptance of any accompanying royalty payment shall not prevent Lender from at any time within three years after the Term of this Agreement questioning the validity or accuracy of such royalty statement or payment.",
    "ollama_generated": "(vii) Submission or acknowledgement by Borrower (or its designated agent) of a royalty declaration or acceptance of any accompanying royalty remittance shall not constitute a waiver of Borrower's right, at any point within three years following the Agreement's expiry, to challenge the legitimacy or correctness of such royalty declaration or payment. This provision serves to protect Lender's interest in maintaining scrutiny over the accuracy and validity of royalties received during the term of this Agreement, even after it has ended.",
    "contradiction_score": 0.01365413423627615,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 53,
    "start_char": 27252,
    "end_char": 29425,
    "original": "(a) Within three (3) days of the execution and delivery of this Agreement and prior to any news release or public disclosure of the existence of this Agreement, its terms and conditions, or the relationship of the parties hereto, whether pursuant to a press release, a current report on Form 8-K or other filing with the Securities and Exchange Commission or otherwise (the \u201cIssuance Date\u201d), MusclePharm shall issue Lender 780,000 shares of MusclePharm\u2019s restricted stock (the \u201cCompensation Shares\u201d), for services performed and to be performed pursuant to this Agreement. All Compensation Shares will be fully vested upon issuance, and for a period of six (6) months following the date hereof, Lender may not sell in excess of fifty percent (50%) of the Compensation Shares without the prior consent of MusclePharm\u037e  provided, that, the Lender shall be entitled, without the prior consent of MusclePharm, to transfer the Compensation Shares at any time to affiliates and family members so long as such transfers are in compliance with state and federal securities laws and such transferees agree to be bound by foregoing transfer restrictions for the six (6) month period following the date hereof with respect to the Compensation Shares. MusclePharm agrees that (i) with respect to the Compensation Shares, Lender shall be entitled to all rights and benefits under the registration rights agreement, dated as of March 28, 2013 (the \u201cRegistration Rights Agreement\u201d), by and among MusclePharm and the investors party thereto as if it were an investor party thereto, mutatis mutandis. MusclePharm shall promptly file (and in no event later than August 14, 2013) a registration statement on Form S-1 pursuant to the Securities Act (as defined below) (the \u201cRegistration Statement\u201d) with the SEC and will include therein the offering of all of the Compensation Shares and no other securities of the Company. MusclePharm agrees that if the SEC shall issue comments on the Registration Statement, MusclePharm shall in good faith respond to such comments as soon as practicable. MusclePharm will cause the Registration Statement to be declared effective as promptly as practicable.",
    "ollama_generated": "(a) Prior to any public disclosure or news release regarding this Agreement, its terms, conditions, or the relationship of the parties involved, which may occur through a press release, a Form 8-K filing with the Securities and Exchange Commission, or otherwise (the \"Disclosure Date\"), Lender will be granted 780,000 shares of MusclePharm's restricted stock (the \"Compensation Shares\") in recognition of services already rendered and to be rendered under this Agreement. These Compensation Shares will vest immediately upon issuance, but for a period of six (6) months following the date hereof, Lender may not sell more than fifty percent (50%) of the Compensation Shares without MusclePharm's prior written consent; however, Lender shall be permitted to transfer the Compensation Shares to affiliates and family members at any time, provided that such transfers comply with applicable state and federal securities laws and the recipients agree to adhere to the same six-month transfer restrictions as Lender. MusclePharm acknowledges that (i) Lender shall enjoy all rights and benefits under the registration rights agreement, dated March 28, 2013 (the \"Registration Rights Agreement\") between MusclePharm and the investors therein, to the extent applicable. MusclePharm undertakes to file a registration statement on Form S-1 pursuant to the Securities Act, no later than August 14, 2013, for the offering of all Compensation Shares, but not any other Company securities (the \"Registration Statement\"). MusclePharm accepts responsibility for addressing any comments made by the SEC on the Registration Statement in a timely and good-faith manner, and will work diligently to have the Registration Statement declared effective as soon as feasible.",
    "contradiction_score": 0.18095476925373077,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 58,
    "start_char": 32520,
    "end_char": 33043,
    "original": "(iii) Lender, or Lender\u2019s business and financial advisors, have substantial experience in evaluating and investing in private transactions of securities in companies similar to MusclePharm and such other company and Lender acknowledges that it can protect its own interests. Lender, or such advisors, have such knowledge and experience in financial and business matters so that it is capable of evaluating the merits and risks of its acceptance of all of the Compensation Shares of MusclePharm as compensation or otherwise.",
    "ollama_generated": "(iii) Borrower acknowledges that while the Lender, or its financial advisors, may have experience in evaluating and investing in private transactions involving securities similar to MusclePharm, this expertise does not absolve the Borrower of the responsibility to demonstrate the suitability and merits of accepting any Compensation Shares from MusclePharm. The Borrower understands that it is ultimately responsible for its own due diligence in assessing the risks associated with such acceptance.",
    "contradiction_score": 0.005569469183683395,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 59,
    "start_char": 33043,
    "end_char": 33210,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (iv) Lender is an \u201caccredited investor\u201d within the meaning of Rule 501 of Regulation D promulgated under the Securities Act.",
    "modified": "Clause:\nNew Meaning: The Borrower declares that they possess the necessary qualifications to be considered a \"non-accredited investor\" as defined by Rule 506 of Regulation D enacted under the Securities Act. In other words, they do not meet the criteria for an accredited investor, thus enabling them to participate in certain securities offerings.",
    "contradiction_score": 0.9674690961837769,
    "kept": true
  },
  {
    "clause_index": 60,
    "start_char": 33210,
    "end_char": 34337,
    "original": "(v) Lender understands that all books, records, and documents of MusclePharm relating to it have been and remain available for inspection by him or his business and financial advisors upon reasonable notice. Lender confirms that all documents requested have been made available, and that it or such advisors have been supplied with all of the information concerning MusclePharm that has been requested. Lender confirms that it or such advisors have obtained sufficient information, in its and their judgment to evaluate the merits and risks of receipt of the Compensation Shares as compensation or otherwise. Lender confirms that it has had the opportunity to obtain such independent legal and tax advice and financial planning services as it has deemed appropriate prior to making a decision to enter this Agreement. In making each such decision, Lender has relied exclusively upon its experience and judgment, or that of such advisors, upon such independent investigations as it, or they, deemed appropriate, and upon information provided by MusclePharm in writing or found in the books, records, or documents of MusclePharm.",
    "ollama_generated": "(vi) Borrower acknowledges that all financial records, documents, and books pertaining to MusclePharm have been and will continue to be accessible for review by us or our professional advisors, upon a reasonable notice. We declare that all documents sought have been furnished, and we confirm that our advisors or we have received all relevant information about MusclePharm that has been requested. We affirm that our advisors or we possess the necessary information, in their judgment, to assess the advantages and potential risks associated with receiving the Compensation Shares as remuneration or otherwise. We affirm that we have had the chance to procure independent legal counsel, tax advice, and financial planning services considered suitable by us prior to agreeing to this Contract. In exercising each such choice, we have relied solely on our expertise and judgment, or that of our advisors, upon investigations deemed appropriate by us or them, and on information provided by MusclePharm in writing or found within the financial records, documents, or books of MusclePharm. However, it is explicitly understood that while we have made every effort to ensure the accuracy and completeness of this information, any potential errors or omissions may exist and are solely our responsibility.",
    "contradiction_score": 0.009249581955373287,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 61,
    "start_char": 34337,
    "end_char": 34810,
    "original": "(vi) Lender is aware that the economic ownership of the Compensation Shares is highly speculative and subject to substantial risks. Lender is capable of bearing the high degree of economic risk and burdens of this venture, including, but not limited to, the possibility of a complete loss, the lack of a sustained and orderly public market, and limited transferability of the Compensation Shares, which may make the liquidation thereof impossible for the indefinite future.",
    "ollama_generated": "(vi) Borrower acknowledges that the economic ownership of the Compensation Shares involves significant speculative risks and potential losses. Lender understands these inherent risks and is not obligated to shoulder them, but rather expects to benefit from this venture. The Lender may not necessarily be able to recover the full investment, given the absence of a reliable public market and the restricted transferability of the Compensation Shares, rendering their liquidation problematic for an extended period.",
    "contradiction_score": 0.012929948046803474,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 76,
    "start_char": 40880,
    "end_char": 41211,
    "original": "(iii) This Agreement may also be terminated by MusclePharm, upon fifteen days prior written notice, if death, or physical disability, physical injury, or other incapacity lasting more than eight (8) weeks, causes Endorser to be unable to perform a material amount of the personal or consulting services described in this Agreement.",
    "ollama_generated": "(iii) This Agreement may be unilaterally terminated by MusclePharm with fifteen days' written notice, effective immediately, if an event beyond Endorser's control, such as death, severe illness or injury leading to prolonged incapacity exceeding eight (8) weeks, prevents them from fulfilling a substantial portion of the personal or consulting services outlined in this Agreement. In such cases, MusclePharm shall not be held liable for any obligations or commitments that remain unfulfilled as a result of Endorser's incapacity.",
    "contradiction_score": 0.01037236675620079,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 79,
    "start_char": 43575,
    "end_char": 47321,
    "original": "(v) In the event Musclepharm is in material breach or default of this Agreement, the AS Parties may give written notice to Musclepharm of intent to terminate, and such notice shall set forth in reasonable detail the facts, circumstances or events causing the alleged breach or default (\u201cMusclePharm Events of Default\u201d). Musclepharm shall have thirty (30) days\u2019 notice in which to cure the MusclePharm Events of Default to the reasonable and objective satisfaction of the terminating party. If Musclepharm fails, refuses or is unable for any reason to cure the MusclePharm Events of Default to the reasonable and objective satisfaction of the terminating party, then the the AS Parties may terminate this Agreement by giving a written termination notice which shall be effective on third calendar day after the date of the termination notice (c) Effect of Expiration/Termination: Upon expiration or termination of the Agreement for pursuant to Section 9 herein, Endorser shall have no further obligation to render any services whatsoever. MusclePharm shall have no further right to use the rights granted to MusclePharm hereunder and all such rights (including without limitation the rights to use the Name and Appearance Rights and Trademarks) shall immediately and automatically be revoked and shall terminate and revert to the AS Parties immediately with no \u201cuse-up period\u201d. Notwithstanding the foregoing, in the event the expiration of this Agreement or termination of this Agreement by Musclepharm pursuant to paragraph 9(a), MusclePharm shall be entitled to sell-off the remaining Licensed Products for six (6) months after such expiration of this Agreement pursuant to paragraph 4(d) herein and shall continue to pay Endorser the Royalty set forth in paragraph 7 herein. MusclePharm shall not be liable to pay any compensation for services performed after the expiration or termination. In the event of a termination by MusclePharm pursuant to paragraph 9(a)(i)-(ii), Musclepharm shall not be required to pay Endorser any further compensation except for Royalties earned up until such termination date, and provided, however, that if Musclepharm terminates this Agreement because of death, disability, physical injury, or other incapacity of Endorser, if Endorser has performed all services required by this Agreement for a particular Contract Year, then MusclePharm shall continue to be obligated to compensate Lender with the full compensation amount of this Agreement for such Contract Year. Notwithstanding anything contained herein, irrespective of the expiratation or termination of this Agreement, the AS Parties shall always be entitled to retain and shall never be obligated to return any monies paid and/or stock issued to Lender and/or Endorser pursuant to this Agreement. All formulas used in the Licensed Products shall remain the property of MusclePharm, but all rights in any packaging, promotional materials, and websites of the Licensed Products (including, without limitation, pictures, the name, logos and trade dress) and all intellectual property of the AS Parties shall revert back or otherwise be vested in the AS Parties\u037e provided, however, that the MusclePharm trade name, any MusclePharm trademarks, and MusclePharm logo used on the Licensed Products shall remain the property of MusclePharm. The AS Parties shall also have the right to purchase from MusclePharm the Arnold.com domain name for a purchase price equal to MusclePharm\u2019s actual cost in acquiring such domain name (in the amount of Twenty Seven Thousand Five Hundred ($27,500) plus interest accruing at an annual rate of five percent (5%) from April 27, 2013 the date of acquisition of such domain name through the date of the sale of such domain name.",
    "ollama_generated": "(v) In case Musclepharm breaches or defaults materially under this Agreement, the AS Parties retain the discretion to issue a written notice specifying their intention to terminate. Such notice will outline the grounds for the alleged violation (\"MusclePharm Non-compliance Issues\"). Upon receipt of such notice, Musclepharm shall have thirty (30) days to rectify the identified non-compliance issues to the satisfaction of the party exercising the termination option. If Musclepharm fails or declines to meet this requirement within the stipulated timeframe or for any reason is unable to comply with the requested corrections, the AS Parties may elect to terminate this Agreement by providing a written termination notice. This termination will become effective thirty-six (36) hours after the delivery of the termination notice.\n\n  (c) Consequences of Termination/Expiration: Upon termination or expiration of the Agreement, as detailed in Section 9 herein, the Endorser shall have no obligation to perform any further services. Musclepharm shall retain the rights granted under this Agreement for a period of six (6) months following such termination or expiration, during which they may sell off remaining Licensed Products according to paragraph 4(d). However, Musclepharm will no longer be entitled to receive any royalties after this six-month period and shall not claim compensation for services rendered post-termination/expiration.\n\nIn the event that Musclepharm terminates this Agreement due to causes listed in paragraph 9(a)(i)-(ii), they shall owe no further compensation to Endorser, except for any royalties earned up until the date of termination. Notably, if Musclepharm terminates the Agreement because of the death, disability, injury, or incapacity of the Endorser, and the Endorser has fulfilled all obligations required by this Agreement during a particular Contract Year, then Musclepharm will remain liable to pay the Lender the full compensation amount specified in the Agreement for that Contract Year. In all cases, the AS Parties reserve the right to retain any monies paid and/or stock issued under this Agreement without being obligated to return them.\n\nAll formulas used in the Licensed Products will remain the property of MusclePharm, but all rights in packaging materials, promotional resources, and websites related to the Licensed Products (including images, names, logos, and trade dress) and intellectual property owned by the AS Parties will revert or be transferred back to them. The AS Parties may, however, opt to purchase from Musclepharm the Arnold.com domain name for a price equal to the actual cost incurred by MusclePharm in acquiring this domain name (currently Twenty Seven Thousand Five Hundred dollars ($27,500) plus accrued interest at an annual rate of five percent (5%) from April 27, 2013 up until the date of sale.)",
    "contradiction_score": 0.10348271578550339,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 47321,
    "end_char": 47377,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 10. Expenses:",
    "modified": "Clause:\nSource: REINVIGORATED BIOTECH INC., 10-K/A, 3/15/2023 - 9. Expenditures:\n\nThe Company shall not be responsible for reimbursing any expenses incurred by the Shareholder unless such expenses are expressly approved in writing by the Company's Chief Financial Officer (CFO) prior to their incurrence, and such expenses are reasonable, necessary, and directly related to the Shareholder's performance of his/her duties as a Shareholder. In case of any dispute regarding the reasonableness, necessity or relation of such expenses, the decision of the Company's Board of Directors shall be final and binding on all parties involved.",
    "contradiction_score": 0.6834082007408142,
    "kept": true
  },
  {
    "clause_index": 81,
    "start_char": 47377,
    "end_char": 47794,
    "original": "In connection with any Appearance or Production Day that Endorser shall be required to specifically travel solely for MusclePharm to make such Appearance or Production Day and shall not already be in such geographic location for another commitment, MusclePharm shall be required to pay the expenses associated with Endorser\u2019s travel, lodging, security and other expenses as set forth on  Exhibit \u201cD\u201d  attached hereto.",
    "ollama_generated": "Should a situation arise where the Endorser is requested to attend an Appearance or Production Day exclusively for MusclePharm and such event necessitates travel from a location where the Endorser has no existing commitments, the responsibility for covering the Endorser's travel expenses, lodging, security, and other costs as detailed in Exhibit \"D\" attached herewith, shall fall upon MusclePharm. However, if the Endorser is already present at the required location due to another commitment, these expenses will not be reimbursed by MusclePharm.",
    "contradiction_score": 0.04178153723478317,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 87,
    "start_char": 49153,
    "end_char": 49217,
    "original": "12. Sales and Marketing Plan And AS Product Line and Trademarks:",
    "ollama_generated": "12. Sales and Marketing Strategies, along with the AS Product Range and Trademarks Implications:\n\nIn this revised clause, we have shifted the focus from a plan to strategies, which might imply a more flexible approach to sales and marketing activities. Additionally, we have used \"implications\" instead of \"line,\" suggesting a broader consideration of potential impacts or consequences when using the AS product range and trademarks. This change subtly indicates a more cautious or responsible attitude towards the use of these elements.",
    "contradiction_score": 0.09129241853952408,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 89,
    "start_char": 49703,
    "end_char": 51094,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) Prior to the execution and delivery of this Agreement with respect to the First Contract Year and at least ninety (90) days prior to the beginning of each Contract Year of the Term, MusclePharm will provide the AS Parties with a detailed marketing plan (the \u201cMarketing Plan\u201d). The AS Parties shall be entitled to approve the Marketing Plan, such approval not to be unreasonably withheld or delayed. MusclePharm shall use its commercially reasonable efforts to market and distribute the Licensed Products, and MusclePharm shall allocate between $3,000,000 and $5,000,000 in the First Contract Year and $5,000,000 in each subsequent Contract Year (including any renewal terms if any) toward the marketing of the Licensed Products (the \u201cMarketing Budget\u201d)\u037e it being understood that the parties may mutually decide not to deploy the full Marketing Budget in any Contract Year if in the good faith determination by the parties that the deployment of the full Marketing Budget is unnecessary to achieve its projected revenue targets in connection with the sale of the Licensed Products. Notwithstanding the foregoing, MusclePharm shall be entitled to re-allocate marketing dollars in its good faith judgment exercisable in its sole discretion from the media forms set forth in the Marketing Plan to promote the Licensed Products in other media forms.",
    "ollama_generated": "Clause:\n\nOrigin: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) At least ninety (90) days prior to the beginning of each Contract Year, MusclePharm shall provide the AS Parties with a marketing plan (the \u201cMarketing Plan\u201d). The Marketing Plan is intended as a guideline and may be subject to adjustments at the sole discretion of MusclePharm. The AS Parties reserve the right to express concerns or suggestions about the Marketing Plan, but MusclePharm will not be bound by their approval, nor shall any delay in providing such approval be deemed a breach of this Agreement.\n\nMusclePharm commits to using its best efforts to market and distribute the Licensed Products, with a minimum budget allocation of $3,000,000 for the First Contract Year and $5,000,000 in each subsequent Contract Year (including any renewal terms if any). However, it is understood that either party may elect to reduce the marketing budget in any Contract Year if they jointly determine that a reduction is necessary to meet projected revenue targets for the Licensed Products. Notwithstanding the foregoing, MusclePharm retains the discretionary power to re-allocate marketing funds to alternate media forms as it deems fit to promote the Licensed Products effectively.",
    "contradiction_score": 0.34082332253456116,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 94,
    "start_char": 53862,
    "end_char": 54552,
    "original": "Should the AS Parties fail to respond in this last Five (5) business day period, submission shall be deemed approved. In addition, MusclePharm shall send, at its expense, at a minimum, two (2) representative samples of each Licensed Products, at each of the concept, pre-production and production stages, to the AS Parties at the address set forth in Section 20 below for prior approval. During the Term, MusclePharm will also send two (2) representative samples of the Licensed Products to the AS Parties at the address set forth in Section 20 below upon request so that the AS Parties can determine whether the quality of the Licensed Products bearing the Endorser IP is being maintained.",
    "ollama_generated": "In case the AS Parties do not respond within the last Five (5) business day period, it will be considered as implied consent for submission approval. Furthermore, MusclePharm is responsible for sending, at its own expense, a minimum of two (2) representative samples of each Licensed Product at each concept, pre-production, and production stage to the AS Parties at the address stated in Section 20 below, for their review prior to approval. Throughout the Term, MusclePharm will also send two (2) representative samples of the Licensed Products to the AS Parties at the aforementioned address upon their request, enabling them to assess whether the quality of the Licensed Products bearing the Endorser IP remains consistent.",
    "contradiction_score": 0.0016683496069163084,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 95,
    "start_char": 54552,
    "end_char": 55449,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) MusclePharm shall at all reasonable times during the Term (but no more than once during each Contract Year of the Term), and upon reasonable notice, permit the AS Parties to send their authorized representatives to inspect the facilities of MusclePharm or its agents in order to confirm that the production of the Licensed Products hereunder is in compliance with the quality standards set out herein and, at MusclePharm\u2019s expense, randomly test the formulas of the Licensed Products for quality control purposes, although the AS Parties will have no obligation to do (c) The Licensed Products shall be of the highest quality and manufactured, produced, sold, distributed and promoted in strict compliance with all applicable laws and regulations, and be of substantially the same or better quality as the samples previously submitted by MusclePharm.",
    "ollama_generated": "Clause:\nSource: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) MusclePharm may grant, at its sole discretion and without obligation to do so, the AS Parties permission to inspect its facilities or those of its agents during the Term, although such inspections shall be limited to no more than once per Contract Year. Notice for these inspections must be deemed reasonable by MusclePharm. (c) The Licensed Products are expected to meet quality standards as outlined herein, but MusclePharm shall not be held responsible for any deviations from the samples previously submitted, provided that the Licensed Products are manufactured, produced, sold, distributed and promoted in compliance with all applicable laws and regulations.",
    "contradiction_score": 0.023276574909687042,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 99,
    "start_char": 56631,
    "end_char": 56831,
    "original": "(i) MusclePharm and the manufacturers will not use child labor (not including child actors or models) in the manufacturing, packaging, marketing, advertising, or distribution of the Licensed Products.",
    "ollama_generated": "(i) The use of child labor, excluding child actors or models, in any stage of the production, promotion, or distribution of the Licensed Products shall be explicitly prohibited by MusclePharm and the manufacturers, unless required by local laws or exceptions specifically approved in writing.",
    "contradiction_score": 0.0007105562835931778,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 107,
    "start_char": 58370,
    "end_char": 58641,
    "original": "(ix) If MusclePharm becomes aware that any manufacturer has used or is using Endorser IP for any unauthorized purpose, MusclePharm, will immediately notify the AS Parties and, if so instructed by the AS Parties, will cause such manufacturer to cease such use immediately.",
    "ollama_generated": "(ix) In the event that MusclePharm detects a manufacturer utilizing Endorser IP for purposes not authorized, MusclePharm shall promptly inform the AS Parties. If it is determined by the AS Parties that action should be taken, MusclePharm will endeavor to facilitate such action by the manufacturer within a reasonable timeframe, but shall not be held liable for any continued or subsequent use of the Endorser IP by the manufacturer unless such use occurs after MusclePharm's reasonable attempts at compliance have been exhausted.",
    "contradiction_score": 0.0008647520444355905,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 108,
    "start_char": 58641,
    "end_char": 58846,
    "original": "(f) Unless the AS Parties expressly agree in advance and in writing otherwise, all Licensed Products shall be manufactured within the fifty states of the United States of America and in no other locations.",
    "modified": "(f) Absent a prior, explicit, and written agreement from the AS Parties, any Manufacturing of Licensed Products will not be confined to the United States of America, but may extend to international locations as well.",
    "contradiction_score": 0.9626389145851135,
    "kept": true
  },
  {
    "clause_index": 115,
    "start_char": 61728,
    "end_char": 62004,
    "original": "(f) Injunctive Relief . MusclePharm acknowledges that the unauthorized use of the Name and Appearance Rights and Trademarks will result in immediate and irreparable damages to the AS Parties and that the AS Parties would have no adequate remedy at law for such authorized use.",
    "modified": "(f) Injunctive Relief . MusclePharm recognizes that any unauthorized use of the Name and Appearance Rights and Trademarks may cause substantial, albeit not immediate, harm to the AS Parties, and that, in such cases, monetary damages alone might not fully compensate for this harm. The AS Parties reserve the right to seek injunctive relief to prevent any such unauthorized use.",
    "contradiction_score": 0.5594901442527771,
    "kept": true
  },
  {
    "clause_index": 120,
    "start_char": 64585,
    "end_char": 64606,
    "original": "15. Indemnification .",
    "ollama_generated": "15. Mutual Defense and Hold Harmless Agreement.\n\nIn consideration of the mutual benefits derived from this Agreement, each Party hereby agrees to defend, indemnify, and hold harmless the other Party and its affiliates (if applicable) against any and all losses, damages, liabilities, claims, actions, judgments, costs, or expenses arising out of or resulting from any third-party claim based upon a breach of this Agreement by the indemnifying Party or the indemnifying Party's negligent acts or omissions. The indemnification obligation under this section shall survive termination or expiration of this Agreement.\n\nIn other words, each Party is agreeing to take responsibility for any third-party claims resulting from their breach of this agreement or their own negligence, and they will defend, protect, and compensate the other Party for any losses that may arise as a result. This obligation remains even after the agreement has ended.",
    "contradiction_score": 0.004846932366490364,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 128,
    "start_char": 68815,
    "end_char": 69100,
    "original": "The license granted by this Agreement is personal to MusclePharm. Except as set forth below, MusclePharm shall not assign or otherwise transfer, license, sublicense, or delegate any rights or obligations under this Agreement without the express prior written consent of the AS Parties.",
    "ollama_generated": "This License granted by the Agreement is exclusively for the use of MusclePharm. Any attempt to assign, transfer, sub-license, or delegate any rights or responsibilities under this Agreement, except as explicitly permitted below, requires prior written consent from all parties involved (AS Parties), which may not be unreasonably withheld.",
    "contradiction_score": 0.0021549316588789225,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 137,
    "start_char": 70965,
    "end_char": 71010,
    "original": "Edward H. Schauder, Esq If to the AS Parties:",
    "ollama_generated": "Emily J. Smith, Esq shall be responsible towards the AB Parties as follows:\n\nEmily J. Smith, Esq shall have no obligation to the AS Parties unless specifically required by applicable law or mutually agreed in writing. In the event that such an obligation arises, Emily J. Smith, Esq shall exercise reasonable efforts to fulfill it, but shall not be held liable for any damages, costs, or losses resulting from her failure to do so unless such failure constitutes gross negligence or willful misconduct on her part. The AS Parties acknowledge and agree that they have no right to seek recourse against Emily J. Smith, Esq for any claims arising out of or related to this agreement, except as expressly provided in this agreement or as required by law.",
    "contradiction_score": 0.40364497900009155,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 141,
    "start_char": 71375,
    "end_char": 71639,
    "original": "Main Street Advisors 3110 Main Street, Suite 310 Santa Monica, CA 90405 Attn: Paul Wachter & Alex Cohen Bloom Hergott Diemer Rosenthal LaViolette Feldman Schenkman & Goodman, LLP 150 South Rodeo Drive, 3rd Floor Beverly Hills, CA 90212 Attn: Patrick M. Knapp, Esq.",
    "ollama_generated": "150 South Rodeo Drive, 3rd Floor Beverly Hills, CA 90212\nAttn: Patrick M. Knapp, Esq.\nBloom Hergott Diemer Rosenthal LaViolette Feldman Schenkman & Goodman, LLP\nMain Street Advisors\n3110 Main Street, Suite 310\nSanta Monica, CA 90405\nAttn: Paul Wachter & Alex Cohen\n\n(Note: The original clause is addressing a specific firm and individuals, but the rewritten version reverses the order and shifts the responsibility of address to the sender.)",
    "contradiction_score": 0.05395929887890816,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 142,
    "start_char": 71639,
    "end_char": 72049,
    "original": "Loeb & Loeb LLP 10100 Santa Monica Blvd., Suite 2200 Los Angeles, Ca 90067 Attn: David W. Grace or to such other address as the parties hereto may specify, in writing, from time to time. Written notice given as provided in this Section shall be deemed received by the other party two business days after the date the mail is stamped registered or certified and deposited in the mail, or deposited with courier.",
    "ollama_generated": "Recipient's Address:\nLoeb & Loeb LLP, 10100 Santa Monica Blvd., Suite 2200, Los Angeles, CA 90067, Attn: David W. Grace, or to any alternative address notified in writing by one party to the other from time to time. Notifications made as per this section shall be considered received by the recipient five business days following the date of mailing, either via registered post or certified mail, or through a courier service.\n\nChanges:\n- Changed \"written notice given as provided in this Section shall be deemed received\" to \"Notifications made as per this section shall be considered received\". This slightly weakens the obligation by changing the certainty of immediate receipt upon deposit to considering receipt five business days later.\n- Adjusted the time frame for receipt from two to five business days. This extends the possible response time, potentially providing more flexibility for the recipient.",
    "contradiction_score": 0.041559502482414246,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 147,
    "start_char": 73535,
    "end_char": 74176,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 (b) In any arbitration arising out of or related to this Agreement, the arbitrator(s) shall award to the prevailing party, if any, the costs and attorneys\u2019 fees reasonably incurred by the prevailing party in connection with the arbitration. If the arbitrator(s) determine a party to be the prevailing party under circumstances where the prevailing party won on some but not all of the claims and counterclaims, the arbitrator(s) may award the prevailing party an appropriate percentage of the costs and attorneys\u2019 fees reasonably incurred by the prevailing party in connection with the arbitration.",
    "modified": "Clause:\nSource: REVISED ENTITY, Annual Report, 2/8/2017 (b) In any arbitration stemming from or associated with this Agreement, the arbitrator(s) shall apportion to the non-prevailing party, if applicable, a portion of the costs and legal fees incurred by the opposing party in the course of the arbitration. If the arbitrator(s) deem a party to have not prevailed entirely but to have won on some claims or counterclaims, the arbitrator(s) may assign a proportionate share of the costs and legal fees incurred by the non-prevailing party relative to the claims on which they were successful. In such cases where both parties achieve success in their respective claims, the arbitrator(s) shall use their discretion to equitably distribute the costs and attorneys' fees among the parties involved.",
    "contradiction_score": 0.8330540657043457,
    "kept": true
  },
  {
    "clause_index": 148,
    "start_char": 74193,
    "end_char": 74212,
    "original": "23. Binding Effect:",
    "ollama_generated": "23. Durability of Obligations:\n\nThe parties hereto acknowledge and agree that the commitments and obligations undertaken herein shall persist and remain binding, notwithstanding any future modifications or amendments to this Agreement, unless otherwise expressly provided for in writing by all parties concerned.",
    "contradiction_score": 0.0106863584369421,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 152,
    "start_char": 75803,
    "end_char": 76653,
    "original": "(b) MusclePharm represents, warrants and covenants that (i) it has the full right, power and authority to enter into this Agreement\u037e (ii) it has acquired all rights necessary to perform this Agreement and exploit the Licensed Products as contemplated herein\u037e (iii) the Licensed Products, any element thereof, or any advertising, promotional or publicity materials supplied by Licensee or third parties hereunder will not contain any language or material which is obscene, libelous, slanderous or defamatory\u037e (iv) the use of the Licensed Product and the Name and Appearance Rights as contemplated herein will not violate or infringe the copyright, trademark, or other rights of any third party\u037e (v) the Products and Licensed Products will comply in all material respects with all applicable laws and regulations and will be safe for human consumption.",
    "modified": "(b) MusclePharm acknowledges, affirms, and undertakes as follows:\n  (i) MusclePharm acknowledges that it holds the complete authority, capacity, and legal right to execute this Agreement.\n  (ii) MusclePharm understands that it may not have all necessary rights to fulfill this Agreement or exploit the Licensed Products in the manner envisioned herein; however, it shall take reasonable steps to obtain any required rights.\n  (iii) MusclePharm accepts no responsibility for ensuring that the Licensed Products, any component thereof, or any promotional materials provided by Licensee or third parties will not contain language or material deemed obscene, libelous, slanderous, or defamatory; it is the sole responsibility of Licensee and third parties to ensure compliance.\n  (iv) MusclePharm assumes no liability for potential violations or infringements of the copyright, trademark, or other rights of any third party arising from the use of the Licensed Product, Name, and Appearance Rights as specified in this Agreement.\n  (v) The Products and Licensed Products may not necessarily comply with all applicable laws and regulations, and it is not guaranteed that they will be safe for human consumption; Licensee assumes full responsibility for ensuring compliance with all relevant laws and the safety of the products.",
    "contradiction_score": 0.6331436038017273,
    "kept": true
  },
  {
    "clause_index": 153,
    "start_char": 76653,
    "end_char": 76710,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 25. Payments :",
    "ollama_generated": "Clause:\nRevised for MUSCLEPHARM CORP, 10-K/A, 2/8/2017 - 25. Remunerations:\n\nIn case of any remuneration due to the Directors or Officers under this Section, it is explicitly understood that such compensation shall be contingent upon the discretion and approval of the Board of Directors, taking into account the company's financial position, performance, and future prospects. Further, the Board reserves the right to withhold, alter, or reduce any remuneration if it deems necessary in light of the above factors or any other relevant circumstances that may arise.",
    "contradiction_score": 0.062233589589595795,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 157,
    "start_char": 77776,
    "end_char": 77791,
    "original": "27. Insurance :",
    "modified": "27. Insurance Obligations:\n\nIn the event of any loss, damage, or liability arising from this agreement, the party incurring such incident shall promptly notify the other and take reasonable measures to mitigate further harm, but shall not be under any obligation to pursue a claim with an insurance provider unless expressly agreed upon by both parties. The risk of uninsured losses remains solely with the non-negligent party.",
    "contradiction_score": 0.7546191215515137,
    "kept": true
  },
  {
    "clause_index": 159,
    "start_char": 79862,
    "end_char": 79927,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 28. Entire Agreement :",
    "modified": "MUSCLEPHARM CORP, 10-K/A, 2/8/2017 - 28. Entire Understanding:\n\nIn the event that this Agreement, in any form, constitutes the entirety of the mutual understanding between the Parties concerning the matters discussed, then neither Party shall be obligated to honor any oral or written agreements outside of this Agreement unless explicitly stated otherwise within this Document. The onus is on either Party to provide evidence of any such additional agreements. In the absence of such evidence, it shall be deemed that no such agreement exists.",
    "contradiction_score": 0.7543773055076599,
    "kept": true
  },
  {
    "clause_index": 165,
    "start_char": 82193,
    "end_char": 82517,
    "original": "* * * THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.  * * * Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 This Agreement when signed and dated by all parties shall be deemed to be made, accepted and delivered in the City and County of Los Angeles, California, regardless of where the Agreement is executed by the parties.",
    "ollama_generated": "* * * THE BALANCE OF THIS PAGE IS INTENTIONALLY UNAfilled.  * * * Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 This Agreement shall be considered as made, accepted, and delivered in any location where a party may choose to sign it, with the City and County of Los Angeles, California, serving only as the initial agreed location upon its drafting.\n\nChanges: The original clause specifies that the agreement is to be deemed made in Los Angeles regardless of execution locations. The rewritten clause allows for any location to serve as the signing location, but Los Angeles remains the initial agreed location.",
    "contradiction_score": 0.1759459674358368,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 170,
    "start_char": 83061,
    "end_char": 83281,
    "original": "Each and every of the foregoing Promotional Products must be specifically approved in advance and in writing by the AS Parties and shall always prominently include the MusclePharm logo or images of the Licensed Products.",
    "modified": "The AS Parties reserve the right to approve, in writing and at their discretion, any Promotional Product used hereafter. While inclusion of the MusclePharm logo or images of the Licensed Products is encouraged, it is not mandatory for every instance. The AS Parties shall not be held responsible for any unapproved or non-branded Promotional Products used in violation of this agreement.",
    "contradiction_score": 0.7785352468490601,
    "kept": true
  },
  {
    "clause_index": 172,
    "start_char": 83565,
    "end_char": 83886,
    "original": "Invoice Returns Royalty Percentage Royalty Amount Total Royalty Earned This Quarter:  $ Total Earned Royalty To Date (This Contract Year):  $ TOTAL  $ Less Paid and Un-Recouped Minimum Guarantee:  $ ([ ]) Balance Due From the Company and  Payable This Quarter:  $ I hereby certify that the above is accurate and complete.",
    "ollama_generated": "Royalty Percentage for Invoiced Returns, Royalty Amount Earned This Quarter:  $\n   Total Earned Royalty to Date (This Contract Year):  $ TOTAL  $\n   Less any Paid and Un-Recouped Minimum Guarantee:  $ [()]\n   The Company owes this balance as the Remaining Due:  $\n   I hereby certify that the above is accurate and complete.\n\nIn this version, the original clause emphasized the total royalty earned and balance due from the company, while inverting the focus to the amount the company still owes (the remaining due) by the end of the quarter.",
    "contradiction_score": 0.016784343868494034,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 175,
    "start_char": 84218,
    "end_char": 84232,
    "original": "Date Received:",
    "ollama_generated": "Date of Delivery:\n\n[Explanation]\nIn the original clause, the focus is on the date when the document was received by the recipient. In this revised version, the emphasis is shifted to the date when the document should be delivered or submitted by the sender. This change subtly implies that the onus of responsibility for timely delivery has been shifted from the recipient to the sender.",
    "contradiction_score": 0.005033486057072878,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 179,
    "start_char": 85031,
    "end_char": 85541,
    "original": "Contract Year  Minimum Royalty  Timing of Payment Four  $2,500,000  $833,333.33 payment due on the following dates: July 23, 2016\u037e October 1, 2016\u037e February 1, 2017 Five  $2,500,000  $833,333.33 payment due on the following dates: July 23, 2017\u037e October 1, 2017\u037e February 1, 2018 Six  $2,500,000  $833,333.33 payment due on the following dates: July 23, 2018\u037e October 1, 2018\u037e February 1, 2019 Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Section (3) Guaranteed Minimum Royalty during the Second Additional Term:",
    "modified": "Contract Year Minimum Royalty Timing of Payment Six\n   $2,500,000  $833,333.33 payment is optional for the Licensor on the following dates: July 23, 2019; October 1, 2019; February 1, 2020\n   $2,500,000  $833,333.33 payment is optional for the Licensor on the following dates: July 23, 2020; October 1, 2020; February 1, 2021\n   $2,500,000  $833,333.33 payment is optional for the Licensor on the following dates: July 23, 2021; October 1, 2021; February 1, 2022\n   Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017 Section (3) Optional Minimum Royalty during the Second Additional Term:",
    "contradiction_score": 0.6921536326408386,
    "kept": true
  },
  {
    "clause_index": 184,
    "start_char": 86909,
    "end_char": 86988,
    "original": "Not approved, pending changes indicated. Re-submit concept sample for approval.",
    "ollama_generated": "Modifications required prior to approval. Kindly revise your submitted concept sample accordingly and resubmit for reevaluation.",
    "contradiction_score": 0.0010197594529017806,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 185,
    "start_char": 86991,
    "end_char": 87004,
    "original": "Not approved.",
    "ollama_generated": "The parties reserve the right to disapprove, at their sole discretion, any matter deemed unacceptable or contrary to the spirit of this agreement. Any such disapproval shall be communicated promptly in writing.",
    "contradiction_score": 0.0008772112196311355,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 196,
    "start_char": 87680,
    "end_char": 87722,
    "original": "Source: MUSCLEPHARM CORP, 10-K/A, 2/8/2017",
    "modified": "Clause (Altered):\nSource: REINVIGORATE FITNESS LTD, Annual Report, 9-5-2020\n\nThe Company shall have no liability to the shareholders for any damages or losses arising from the use of its products, except in cases where such damages or losses are directly attributable to the gross negligence or willful misconduct of the Company. In all other instances, the risks and potential damages associated with the use of our products shall be borne exclusively by the shareholders.",
    "contradiction_score": 0.7418144345283508,
    "kept": true
  }
]